Kinaset Therapeutics to Present KN-002 Phase 1 Clinical Study Outcomes at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming oral presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held on February 23-26, 2024. Frazer Morgan, Co-founder and Chief Development Officer, will deliver an oral presentation on outcomes from the Phase 1 evaluation of Kinaset’s lead candidate, KN-002, an orally inhaled novel, pan-JAK inhibitor being advanced for the treatment of moderate to severe asthma.

Presentation Details:
Title: Safety and Pharmacokinetics of Single Ascending Doses of KN-002 in Healthy Volunteers and Multiple Ascending Doses of KN-002 in Subjects with Mild Asthma
Session Title: Old Therapeutics and New Targets in Asthma
Session Date and Time: Saturday, February 24 at 2:00 p.m. ET
Location: Walter E. Washington Convention Center, Washington D.C.

More information on the 2024 AAAAI Annual Meeting can be found here.

About Kinaset Therapeutics, Inc.

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate KN-002 is a novel, pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhaled route of administration. KN-002 is currently being evaluated in a Phase 1b clinical study involving patients with mild to severe asthma and those with COPD (NCT05006521). With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company. See more information at the Company’s website.